Lyra Therapeutics Aktie

Lyra Therapeutics für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A2P36P / ISIN: US55234L1052

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
13.08.2025 04:49:09

Lyra Therapeutics Posts 85% Q2 Loss Drop

Lyra Therapeutics (NASDAQ:LYRA), a clinical-stage biotechnology company focused on chronic rhinosinusitis (CRS) treatments, reported its second quarter 2025 results on August 12, 2025. The most noteworthy item was the recent pivotal ENLIGHTEN 2 clinical trial win for its primary product candidate, paired with significant cost reductions and new financing. The GAAP EPS loss of $5.51 was less negative than analyst expectations, but GAAP revenue was $0.18 million, which was below the GAAP estimate of $0.29 million. Cost controls led to a much lower GAAP net loss compared to Q2 2024. Overall, the period was highlighted by clinical progress, disciplined spending, and while the company remains reliant on future regulatory milestones. Source: Analyst estimates for the quarter provided by FactSet. Lyra Therapeutics develops bioabsorbable implant devices designed to treat chronic rhinosinusitis, an inflammatory nasal condition affecting millions of people. Its lead product candidate, LYR-210, is a long-acting implant intended to deliver steroid therapy directly to the nasal lining over six months. The company is targeting patients who have not responded to standard medical management and may otherwise require surgery.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Analysen zu Lyra Therapeutics Inc Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Q2 Holdings Inc 55,00 0,00% Q2 Holdings Inc